Skip to content

Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy

Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy in Patients With Clinical Complete Response (ConSIBreC): a Randomized Clinical Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06131632
Acronym
ConSIBreC
Enrollment
300
Registered
2023-11-14
Start date
2024-03-01
Completion date
2028-01-01
Last updated
2024-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Breast Cancer

Keywords

inflammatory breast cancer, breast conserving surgery, radical mastectomy

Brief summary

Inflammatory breast cancer is an aggressive and rare form of breast cancer, which accounts for 2-3% of all breast cancers. The classic presentation of inflammatory breast cancer includes erythema, edema, and peau d'orange of at least one/third of the breast. Current treatment of inflammatory breast cancer include: neoadjuvant chemiotherapy, modified radical mastectomy and radiation therapy. In the last two decades the development of new targeted therapies has significantly improved the efficacy of neoadjuvant chemiotherapy allowing a de-escalation of surgical treatment in patients with non-inflammatory breast cancer that achieve clinical complete response. There are few retrospective studies that evaluate implications of surgical treatment on survival among these patients. This may justify trial aims to investigate the possible use of the breast conserving surgery in patients with inflammatory breast cancer that achieve clinical complete response after neoadjuvant chemiotherapy.

Interventions

PROCEDUREBreast conserving surgery

Remove only a small part of the breast

PROCEDURERadical modified mastectomy

Remove all the breast parenchyma, nipple and skin

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with inflammatory breast cancer * Clinical complete response after neoadjuvant chemiotherapy * Targeted tumor * Written informed consent

Exclusion criteria

* Metastasis * Progression disease * Recurrent disease * Contraindications to adjuvant radiation therapy

Design outcomes

Primary

MeasureTime frameDescription
local recurrence rate24 monthsRate of recurrence in the breast parenchyma after conserving surgery vs radical mastectomy

Secondary

MeasureTime frameDescription
local recurrence-free survival24 monthsRate of disease free survival after breast conserving surgery vs radical mastectomy
overall survival24 monthsoverall survival after breast conserving surgery vs radical mastectomy

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026